Clicky

Evotec Ag(EVOTF)

Description: Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services, as well as absorption, distribution, metabolism, excretion, and toxicity services. The company is also involved in investing and developing proprietary assets, including early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. It has a drug discovery and development partnerships with Celgene Corporation; Novo Nordisk A/S; Sanofi; Almirall, S.A.; Ferring Pharmaceuticals; Centogene AG; Immuneering Corporation; and LEO Pharma A/S. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.


Keywords: Biotechnology Life Sciences Pain Diabetes Pharmacology Drug Discovery Partnership Neuroscience Inflammatory Diseases Metabolism Pharmacokinetics Informatics Proteomics Hamburg Pharmaceutical And Biotech Drug Metabolism Drug Discovery Services Evotec City Services Pharmaceutical And Biotechnology Almirall Development Solution Compound Management Diabetic Complications Kinetics Metabolomics

Home Page: www.evotec.com

Essener Bogen 7
Hamburg, 22419
Germany
Phone: 49 40 560 81 0


Officers

Name Title
Ms. Laetitia Rouxel CFO & Member of Management Board
Dr. Cord Dohrmann Ph.D. Chief Scientific Officer & Member of Management Board
Dr. Craig Johnstone Ph.D. COO & Member of Management Board
Dr. Christian Wojczewski Chief Executive Officer
Ms. Aurelie Dalbiez Chief People Officer & Member of Management Board
Mr. Volker Braun Executive VP and Head of Global Investor Relations & ESG
Dr. Christian Dargel EVP Global Head of Legal & Compliance
Gabriele Hansen Senior VP & Head of Global Corporate Communications & Marketing
Dr. Ian M. Hunneyball Senior Vice President of Programme Management & Clinical Operations
Dr. David Hallet Executive Vice President

Exchange: PINK

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 62.8931
Trailing PE: 0
Price-to-Book MRQ: 1.6299
Price-to-Sales TTM: 2.1343
IPO Date:
Fiscal Year End: December
Full Time Employees: 5007
Back to stocks